OBJECTIVE: Adenosine A(2A) receptor activation after lung transplantation attenuates ischemia-reperfusion injury by reducing inflammation. However, the effect of adenosine A(2A) receptor activation in donor lungs before transplant remains ill defined. This study compares the efficacy of 3 different treatment strategies for adenosine A(2A) receptor agonist in a clinically relevant porcine lung transplantation model. METHODS: Mature porcine lungs underwent 6 hours of cold ischemia before allotransplantation and 4 hours of reperfusion. Five groups (n = 6/group) were evaluated on the basis of treatment with ATL-1223, a selective adenosine A(2A) receptor agonist: thoracotomy alone (sham), transplant alone (ischemia-reperfusion), donor pretreatment via ATL-1223 bolus (ATL-D), recipient treatment via ATL-1223 infusion (ATL-R), and a combination of both ATL-1223 treatments (ATL-D/R). Lung function and injury were compared. RESULTS: Blood oxygenation was significantly higher among ATL-D, ATL-R, and ATL-D/R groups versus ischemia-reperfusion (392.0 ± 52.5, 428.9 ± 25.5, and 509.4 ± 25.1 vs 77.2 ± 17.0 mm Hg, respectively, P < .001). ATL-1223-treated groups had lower pulmonary artery pressures (ATL-D = 30.5 ± 1.8, ATL-R = 30.2 ± 3.3, and ATL-D/R = 29.3 ± 4.5 vs IR = 45.2 ± 2.1 mm Hg, P < .001) and lower mean airway pressures versus ischemia-reperfusion (ATL-D = 9.1 ± 0.8, ATL-R = 9.1 ± 2.6, and ATL-D/R = 9.6 ± 1.3 vs IR = 21.1 mm Hg, P < .001). Likewise, ATL-1223-treated groups had significantly lower lung wet/dry weight, proinflammatory cytokine expression, and lung injury scores by histology compared with ischemia-reperfusion. All parameters of lung function and injury in ATL-1223-treated groups were similar to sham (all P > .05). CONCLUSIONS: Pretreatment of donor lungs with ATL-1223 was as efficacious as other treatment strategies in protecting against ischemia-reperfusion injury. If necessary, supplemental treatment of recipients with ATL-1223 may provide additional protection. These results support the development of pharmacologic A(2A)R agonists for use in human clinical trials for lung transplantation.
OBJECTIVE:Adenosine A(2A) receptor activation after lung transplantation attenuates ischemia-reperfusion injury by reducing inflammation. However, the effect of adenosine A(2A) receptor activation in donor lungs before transplant remains ill defined. This study compares the efficacy of 3 different treatment strategies for adenosine A(2A) receptor agonist in a clinically relevant porcine lung transplantation model. METHODS: Mature porcine lungs underwent 6 hours of cold ischemia before allotransplantation and 4 hours of reperfusion. Five groups (n = 6/group) were evaluated on the basis of treatment with ATL-1223, a selective adenosine A(2A) receptor agonist: thoracotomy alone (sham), transplant alone (ischemia-reperfusion), donor pretreatment via ATL-1223 bolus (ATL-D), recipient treatment via ATL-1223 infusion (ATL-R), and a combination of both ATL-1223 treatments (ATL-D/R). Lung function and injury were compared. RESULTS: Blood oxygenation was significantly higher among ATL-D, ATL-R, and ATL-D/R groups versus ischemia-reperfusion (392.0 ± 52.5, 428.9 ± 25.5, and 509.4 ± 25.1 vs 77.2 ± 17.0 mm Hg, respectively, P < .001). ATL-1223-treated groups had lower pulmonary artery pressures (ATL-D = 30.5 ± 1.8, ATL-R = 30.2 ± 3.3, and ATL-D/R = 29.3 ± 4.5 vs IR = 45.2 ± 2.1 mm Hg, P < .001) and lower mean airway pressures versus ischemia-reperfusion (ATL-D = 9.1 ± 0.8, ATL-R = 9.1 ± 2.6, and ATL-D/R = 9.6 ± 1.3 vs IR = 21.1 mm Hg, P < .001). Likewise, ATL-1223-treated groups had significantly lower lung wet/dry weight, proinflammatory cytokine expression, and lung injury scores by histology compared with ischemia-reperfusion. All parameters of lung function and injury in ATL-1223-treated groups were similar to sham (all P > .05). CONCLUSIONS: Pretreatment of donor lungs with ATL-1223 was as efficacious as other treatment strategies in protecting against ischemia-reperfusion injury. If necessary, supplemental treatment of recipients with ATL-1223 may provide additional protection. These results support the development of pharmacologic A(2A)R agonists for use in human clinical trials for lung transplantation.
Authors: S D Ross; I L Kron; J J Gangemi; K S Shockey; M Stoler; J A Kern; C G Tribble; V E Laubach Journal: Am J Physiol Lung Cell Mol Physiol Date: 2000-09 Impact factor: 5.464
Authors: Steven M Fiser; Curtis G Tribble; Stewart M Long; Aditya K Kaza; John A Kern; David R Jones; Mark K Robbins; Irving L Kron Journal: Ann Thorac Surg Date: 2002-04 Impact factor: 4.330
Authors: John C Densmore; Terry R Schaid; Paul M Jeziorczak; Meetha Medhora; Said Audi; Shraddha Nayak; John Auchampach; Melinda R Dwinell; Aron M Geurts; Elizabeth R Jacobs Journal: Exp Lung Res Date: 2017-03-07 Impact factor: 2.459
Authors: Daniel P Mulloy; Ashish K Sharma; Lucas G Fernandez; Yunge Zhao; Christine L Lau; Irving L Kron; Victor E Laubach Journal: Ann Thorac Surg Date: 2013-03-28 Impact factor: 4.330
Authors: Ashish K Sharma; Damien J LaPar; Matthew L Stone; Yunge Zhao; Christopher K Mehta; Irving L Kron; Victor E Laubach Journal: Am J Respir Crit Care Med Date: 2016-05-01 Impact factor: 21.405
Authors: Mary E Huerter; Ashish K Sharma; Yunge Zhao; Eric J Charles; Irving L Kron; Victor E Laubach Journal: Ann Thorac Surg Date: 2016-04-22 Impact factor: 4.330
Authors: J Hunter Mehaffey; Eric J Charles; Ashish K Sharma; Dustin T Money; Yunge Zhao; Mark H Stoler; Christine L Lau; Curtis G Tribble; Victor E Laubach; Mark E Roeser; Irving L Kron Journal: J Thorac Cardiovasc Surg Date: 2016-09-22 Impact factor: 5.209
Authors: Joyce N Gonzales; Boris Gorshkov; Matthew N Varn; Marina A Zemskova; Evgeny A Zemskov; Supriya Sridhar; Rudolf Lucas; Alexander D Verin Journal: Am J Physiol Lung Cell Mol Physiol Date: 2014-01-10 Impact factor: 5.464
Authors: Li Li; Liping Huang; Hong Ye; Steven P Song; Amandeep Bajwa; Sang Ju Lee; Emily K Moser; Katarzyna Jaworska; Gilbert R Kinsey; Yuan J Day; Joel Linden; Peter I Lobo; Diane L Rosin; Mark D Okusa Journal: J Clin Invest Date: 2012-10-24 Impact factor: 14.808
Authors: J Hunter Mehaffey; Eric J Charles; Ashish K Sharma; Morgan Salmon; Dustin Money; Sarah Schubert; Mark H Stoler; Curtis G Tribble; Victor E Laubach; Mark E Roeser; Irving L Kron Journal: Ann Thorac Surg Date: 2017-04-21 Impact factor: 4.330
Authors: Cynthia E Wagner; Nicolas H Pope; Eric J Charles; Mary E Huerter; Ashish K Sharma; Morgan D Salmon; Benjamin T Carter; Mark H Stoler; Christine L Lau; Victor E Laubach; Irving L Kron Journal: J Thorac Cardiovasc Surg Date: 2015-07-30 Impact factor: 5.209